Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31988 | 1.00 | SMYD3 (0.32) | SMYD3KDM1AMAOB | |
| SCHEMBL23489031 | 1.00 | SMYD3 (0.32) | SMYD3KDM1AMAOB | |
| SCHEMBL10198836 | 0.86 | — | — | |
| SCHEMBL20687474 | 0.86 | — | — | |
| SCHEMBL4153538 | 0.86 | — | — | |
| SCHEMBL12219599 | 0.85 | — | — | |
| Cyclohexylamine SCHEMBL6867516 | 0.83 | ALDH1A1 (0.36) | — | |
| SCHEMBL27115503 | 0.82 | SMYD3 (0.31) | SMYD3KDM1AMAOB | |
| SCHEMBL29332587 | 0.78 | GNAI3 (0.30) | — | |
| Cyclohexylamine SCHEMBL8692790 | 0.78 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-11548893-B2 | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection | ARISAN THERAPEUTICS INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11072594-B2 | Trioxolane agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-27 | — | — | US | disclosed |
| US-20210171521-A1 | ENANTIOMERICALLY PURE ADAMANTANE CARBOXAMIDES FOR THE TREATMENT OF FILOVIRUS INFECTION | ARISAN THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-20200140406-A1 | TRIOXOLANE AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-05-07 | — | — | US | disclosed |
| US-8273736-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2012-09-25 | — | — | US | disclosed |
| US-7737160-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100069371-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072594-B2 | Trioxolane agents | ABCB4, SLC10A1, SLC10A2 | SMYD3 3600/4885KDM1A 4175/4885MAOB 4222/4885 |
| US-20200140406-A1 | TRIOXOLANE AGENTS | ABCB4, SLC10A1, SLC10A2 | SMYD3 3600/4885KDM1A 4175/4885MAOB 4222/4885 |
| US-20210171521-A1 | ENANTIOMERICALLY PURE ADAMANTANE CARBOXAMIDES FOR THE TREATMENT OF FILOVIRUS INFECTION | ADRB3, FPR3, RTN3 | SMYD3 1377/4885KDM1A 3745/4885MAOB 495/4885 |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | SMYD3 1144/4885KDM1A 2593/4885MAOB 3347/4885 |
| US-20100069371-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | SMYD3 2260/4885KDM1A 1378/4885MAOB 659/4885 |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | SMYD3 2260/4885KDM1A 1378/4885MAOB 659/4885 |
| US-11548893-B2 | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection | ADRB3, FPR3, RTN3 | SMYD3 1377/4885KDM1A 3745/4885MAOB 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.